Venus Medtech (Hangzhou) Inc.
VMTHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -4.2% | 20.9% | -2.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 78.1% | 79.2% | 77.3% | 78% |
| R&D Expenses | $0 | $1 | $1 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | -$0 |
| % Margin | -73.6% | -120.1% | -160% | -67% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$1 | -$1 | -$1 | -$0 |
| % Margin | -151.7% | -143.2% | -260.2% | -89.8% |
| EPS | -1.63 | -1.61 | -2.42 | -0.85 |
| % Growth | -1.2% | 33.5% | -184.7% | – |
| EPS Diluted | -1.63 | -1.61 | -2.42 | -0.85 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$0 |
| % Margin | -130.2% | -111.5% | -245.9% | -77.9% |